Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more
Hugel Inc - Asset Resilience Ratio
Hugel Inc (145020) has an Asset Resilience Ratio of 29.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Hugel Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hugel Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩307.96 Billion | 29.87% |
| Total Liquid Assets | ₩307.96 Billion | 29.87% |
Asset Resilience Insights
- Very High Liquidity: Hugel Inc maintains exceptional liquid asset reserves at 29.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hugel Inc Industry Peers by Asset Resilience Ratio
Compare Hugel Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Hugel Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Hugel Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 45.04% | ₩423.12 Billion | ₩939.44 Billion | -6.82pp |
| 2023-12-31 | 51.86% | ₩481.93 Billion | ₩929.25 Billion | +1.95pp |
| 2022-12-31 | 49.91% | ₩523.99 Billion | ₩1.05 Trillion | -4.77pp |
| 2021-12-31 | 54.68% | ₩552.13 Billion | ₩1.01 Trillion | -7.98pp |
| 2020-12-31 | 62.66% | ₩599.20 Billion | ₩956.34 Billion | -0.92pp |
| 2019-12-31 | 63.58% | ₩568.80 Billion | ₩894.69 Billion | -1.93pp |
| 2018-12-31 | 65.51% | ₩601.56 Billion | ₩918.27 Billion | -7.05pp |
| 2017-12-31 | 72.56% | ₩595.69 Billion | ₩820.93 Billion | +37.19pp |
| 2016-12-31 | 35.38% | ₩104.11 Billion | ₩294.30 Billion | +32.29pp |
| 2015-12-31 | 3.08% | ₩7.20 Billion | ₩233.57 Billion | -9.54pp |
| 2014-12-31 | 12.63% | ₩12.28 Billion | ₩97.25 Billion | -- |